Quantcast

Latest Silence Therapeutics plc Stories

2010-07-14 01:00:00

LONDON, July 14 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") is pleased to announce a one-year extension of its ongoing research and development collaboration with AstraZeneca.

2010-07-07 01:00:00

LONDON, July 7 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,750,144, titled Methods and Compositions for Enhancing Efficacy and Specificity of RNA Silencing, by the United States Patent and Trademark Office (USPTO).

2010-06-09 01:00:00

LONDON, June 9 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,732,593, titled Methods and Compositions For Controlling Efficacy of RNA Silencing, by the United States Patent and Trademark Office (USPTO).

2010-05-26 01:00:00

LONDON, May 26 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO).

2010-05-11 01:00:00

LONDON, May 11 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that Philip Haworth, Ph.D., chief executive officer, will present corporate updates at two upcoming industry and financial conferences. Dr.

2010-05-05 01:00:00

LONDON, May 5 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the promotion of Jorg Kaufmann, Ph.D., to the position of vice president of research. In this new position, Dr.

2010-04-29 01:00:00

LONDON, April 29 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces its results for the year ended 31 December 2009. On 5 January 2010, Silence merged with U.S.-based RNA interference (RNAi) therapeutic company, Intradigm Corporation, to form a leading company in the field of RNAi.

2010-04-28 01:00:00

LONDON, April 28 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that it will be releasing its preliminary results for the year ended 31 December 2009 on Thursday, 29 April 2010. Analyst Conference Call and Webcast: An analyst briefing call and simultaneous webcast will be held Thursday, 29 April 2010 at 2:00pm BST / 9:00am ET.

2010-04-21 01:00:00

LONDON, April 21 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that the Company and AstraZeneca (LSE: AZN) have agreed to a one-year extension of their ongoing small interfering RNA (siRNA) delivery collaboration.

2010-04-15 01:00:00

LONDON, April 15 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the appointment of Max Herrmann as the Company's chief financial officer and company secretary with effect from May 4, 2010. Mr.


Word of the Day
bowerly
  • Large; stout; burly.
The word 'bowerly' is an alteration of 'burly'.